Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls
GUEST
Erin Raney, PharmD
Professor
Midwestern University College of Pharmacy
GET CE FOR LISTENING!
Stay Compliant. Grow Clinically. Practice with Confidence.
Pharmacist CE Subscription: All your CE in one convenient subscription.
All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!
The Pharmacist CE Subscription includes:
- Compliance and licensure CE
- GameChangers Clinical Updates
- Practical continuing education across patient care topics
*The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training.
PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy.
2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.
Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose.
0.075 CEU/0.75 Hr
UAN: 0107-0000-26-044-H01-P
Initial release date: 1/26/2026
Expiration date: 1/26/2027
Additional CPE details can be found here.
